Navigation Links
Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
Date:2/15/2008

SAN DIEGO, Feb. 15 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that Cadence has received commitments from selected investors to purchase up to 9,240,307 shares of Cadence's common stock at a purchase price of $5.34 per share pursuant to an effective shelf registration statement.

The closing of the offering is expected to take place on February 20, 2008. The total number of shares to be sold in the offering may be reduced to 8,056,716 and the gross proceeds may be reduced to $43.0 million pursuant to Nasdaq Marketplace Rule 4350(i)(1)(B) limitations, pending the determination of the applicability of such rule prior to the closing of the offering.

Copies of the final prospectus supplement and accompanying base prospectus relating to this offering may be obtained from Cadence Pharmaceuticals, Inc., 12481 High Bluff Drive, Suite 200, San Diego, California, Attention: General Counsel, or by calling (858) 436-1400.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter- related infections.

Contacts: William R. LaRue

SVP & Chief Financial Officer

Cadence Pharmaceuticals, Inc.

858-436-1400

Anna Gralinska

Director, Investor Relations

Cadence Pharmaceuticals, Inc.

858-436-1452


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
2. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIO Investor Forum
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/24/2016)... -- Regular discussions on a range of subjects including policies, debt ... said Poloz. Speaking at a lecture to the ... pointed to the country,s inflation target, which is set by ... "In certain areas there needs to ... goals, why not sit down and address strategy together?" ...
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
Breaking Biology News(10 mins):